352 completed, 204 recruiting, 141 unknown, 82 terminated. 275 Phase 2, 164 Phase 3, 128 Phase 1, 117 Not applicable, 90 Phase 4.
Follow Nephritis: new trials by email Literature Review of Nephritis trials Research Report on Nephritis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of NM8074 in Patients With Immunoglobulin A Nephropathy (IgAN) NM8074 - IgA Nephropathy | Phase 2 | Not yet recruiting | NovelMed Therapeutics | 10 | 2028-02-01 | 2026-04-13 |
| CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosus (GALLOP) CB-010 - Systemic Lupus Erythematosus, Lupus | Phase 1 | Withdrawn | Caribou Biosciences, Inc. | 2027-12-01 | 2025-09-19 | |
| A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases CD19-targeted iNKT Cell Injection - IgA Nephropathy (IgAN), Membranous Nephropathy | Early Phase 1 | Not yet recruiting | Grit Biotechnology | 30 | 2027-08-01 | 2026-09-11 |
| Pilot STUDY to Monitor Ex-vivo the Biological Effects of the C3 Inhibitor, PEGCETACOPLAN, on Activation of Complement in Fluid Phase and on Podocytes in Patients With C3G and Primary IC-MPGN Blood sample - Glomerulopathy, C3G | Not yet recruiting | Mario Negri Institute for Pharmacological Research | 25 | 2027-03-01 | 2026-10-29 | |
| A Study to Evaluate the Effectiveness and Safety of Sibeprenlimab in Participants With Primary Membranous Nephropathy, Immune-mediated Focal Segmental Glomerulosclerosis, and Minimal Change Disease Sibeprenlimab - Primary Membranous Nephropathy, Minimal Change Disease | Phase 2 | Not yet recruiting | Otsuka Pharmaceutical Development & Commercialization, Inc. | 20 | 2026-12-15 | 2026-10-06 |
| Efficacy and Safety of Obinutuzumab Beta in Primary IgA Nephropathy With Active Pathological Lesions Obinutuzumab Beta - Primary IgA Nephropathy | Phase 4 | Not yet recruiting | Ruijin Hospital | 20 | 2026-12-10 | 2026-10-22 |
| A Study of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patients With Primary IgA Nephropathy zigakibart, atrasentan, Placebo - IgA Nephropathy (IgAN) | Phase 3 | Not yet recruiting | Novartis Pharmaceuticals | 340 | 2026-12-01 | 2026-09-30 |
| A Phase 3 Blinded Study of JADE101 in Participants With Immunoglobulin A Nephropathy JADE101, Placebo - IgA Nephropathy (IgAN) | Phase 3 | Recruiting | Jade Biosciences, Inc. | 480 | 2026-12-01 | 2026-11-03 |
| MYTP01 for Immune-Mediated Diseases MYTP01, MYTP01 Placebo - IgA Nephropathy, Kidney Transplant Recipients | Not applicable | Not yet recruiting | Zhejiang Provincial People's Hospital | 160 | 2026-12-01 | 2026-11-04 |
| Fosfomycin Trometamol Compared With an Alternative Active Antibiotic as Step-down Therapy for the Treatment of Acute Pyelonephritis Due to Escherichia Coli in Elderly Women : a Randomized, Multicenter, Non-inferiority Trial Fosfomycin-trometamol (FT), Alternative antibiotic treatment - Escherichia Coli Infection, Elderly Women | Phase 3 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 312 | 2026-12-01 | 2026-11-10 |
| A Study to Learn About the Effects of Felzartamab on the Kidneys of Adults With Immunoglobulin A Nephropathy (IgAN) Felzartamab - Immunoglobulin A Nephropathy | Phase 2 | Not yet recruiting | Biogen | 25 | 2026-11-16 | 2026-10-22 |
| A Study to Evaluate the Effect of ARGX-121 on the Change in Proteinuria in Adult Participants With IgAN ARGX-121, Placebo - Immunoglobulin A Nephropathy (IgAN) | Phase 2 | Recruiting | argenx | 120 | 2026-11-05 | 2026-10-27 |
| A Pharmacokinetic Study of Budesonide Delayed Release Tablet D23A (D23) in Healthy Chinese Participants Under Fasting Conditions Budesonide delayed release tablet 4mg, Budesonide Delayed Release Capsules, Budesonide delayed release tablet 16mg - IgA Nephropathy (IgAN) | Phase 1 | Active not recruiting | Triastek, lnc. | 18 | 2026-11-03 | 2026-11-09 |
| Impact of Dapagliflozin for the Regulation of Immunological Activity in Membranous Nephropathy Forxiga - Glomerulonephritis | Phase 2 | Not yet recruiting | Centre Hospitalier Universitaire de Nice | 20 | 2026-11-01 | 2026-06-22 |
| Early PLA2R Status in Severe Anti-PLA2R-mediated Membranous Nephropathy and Long Term Kidney Outcome. Membranous Nephropathy, Major Adverse Kidney Events | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 250 | 2026-11-01 | 2026-11-12 | |
| Optimizing Referral Pathways for Patients With Hematuria and Moderate-Severe Proteinuria Electronic Health Record alert - Referral and Consultation, Glomerulonephritis | Not applicable | Recruiting | Geisinger Clinic | 1200 | 2026-11-01 | 2026-11-12 |
| Single-cell RNA Sequencing (scRNA-seq) to Investigate the Mechanisms Underlying the Induction of Regulatory T Cells in Patients With Extramembranous Glomerulonephritis Treated With Rituximab Peripheral blood immune-cell profiling by single-cell RNA sequencing and in vitro pathway modulation assays - Membranous Nephropathy, Membranous Nephropathy - PLA2R Induced | Not applicable | Not yet recruiting | Centre Hospitalier Universitaire de Nice | 12 | 2026-10-31 | 2026-09-10 |
| Trial of Sibeprenlimab in Children and Adolescents With Immunoglobulin A Nephropathy (IgAN) Sibeprenlimab, Standard of care - IgA Nephropathy | Phase 3 | Not yet recruiting | Otsuka Pharmaceutical Development & Commercialization, Inc. | 24 | 2026-10-30 | 2026-10-15 |
| A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases BMS-986553 - Systemic Lupus Erythematosus, Sjögren's Disease | Phase 1 | Not yet recruiting | Bristol-Myers Squibb | 60 | 2026-10-30 | 2026-10-14 |
| An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Podocyte Diseases ManNAc - Focal Segmental Glomerulosclerosis, Minimal Change Disease | Phase 2 | Recruiting | National Human Genome Research Institute (NHGRI) | 30 | 2026-10-27 | 2026-10-30 |
Showing 20 of 950. Sign in to see all of them.
Lupus Nephritis (336) · Glomerulonephritis, IGA (273) · Lupus Erythematosus, Systemic (134) · Glomerulonephritis, Membranous (116) · Glomerulonephritis (102) · Glomerulosclerosis, Focal Segmental (102) · Proteinuria (93) · Kidney Diseases (76) · Nephrotic Syndrome (53) · Pyelonephritis (51) · Nephrosis, Lipoid (49) · Renal Insufficiency, Chronic (46) · Autoimmune Diseases (45) · Nephritis, Hereditary (39)
Female Urogenital Diseases (949) · Female Urogenital Diseases and Pregnancy Complications (949) · Male Urogenital Diseases (949) · Urogenital Diseases (944) · Urologic Diseases (931) · Kidney Diseases (874) · Glomerulonephritis (745) · Immune System Diseases (738) · Autoimmune Diseases (669) · Skin and Connective Tissue Diseases (404) · Connective Tissue Diseases (387) · Lupus Erythematosus, Systemic (214) · Pathological Conditions, Signs and Symptoms (186) · Pathologic Processes (116)
Mycophenolic Acid (64) · Cyclophosphamide (59) · Prednisone (43) · Rituximab (43) · Tacrolimus (33) · Prednisolone (27) · Adrenal Cortex Hormones (21) · Methylprednisolone (17) · fludarabine (17) · Azathioprine (15) · Blood Specimen Collection (12) · dapagliflozin (12) · voclosporin (12) · Cyclosporine (11) · Glucocorticoids (11)
Novartis Pharmaceuticals (35) · Assiut University (27) · Assistance Publique - Hôpitaux de Paris (20) · Nanjing University School of Medicine (17) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (15) · Mario Negri Institute for Pharmacological Research (13) · Sun Yat-sen University (13) · Guangdong Provincial People's Hospital (11) · Mayo Clinic (10) · Aurinia Pharmaceuticals Inc. (9) · Peking University First Hospital (9) · Alexion Pharmaceuticals, Inc. (8) · Amgen (8) · Biogen (8) · Centre Hospitalier Universitaire de Nice (8)
United States (310) · China (271) · France (118) · Spain (97) · United Kingdom (95) · Germany (91) · Italy (87) · South Korea (77) · Australia (76) · Canada (68) · Taiwan (58) · Argentina (54) · Brazil (54) · Japan (51) · Czechia (50)
Radko Komers, MD, PhD (5) · Fernando C. Fervenza, M.D., Ph.D. (4) · Howard Trachtman, MD (4) · Jeffrey B Kopp, M.D. (4) · Yasar Caliskan, MD (4) · Zhihong Liu, Master (4) · Cheuk-Chun Szeto, MD (3)
PMID 38299639, PMID 34778952, PMID 35224732, PMID 38724717, PMID 37528520, PMID 38864363, PMID 40465397, PMID 26032537, PMID 40337980, PMID 40938675, PMID 26630142, PMID 37772889, PMID 28763548, PMID 33159213, PMID 33693991, PMID 35230699, PMID 37254256, PMID 39513526, PMID 39899371, PMID 10093981, PMID 18930568, PMID 19670912, PMID 20211892, PMID 21303745, PMID 22087680, PMID 28341274, PMID 29450636, PMID 31340979, PMID 33687069, PMID 35675911, PMID 36423588, PMID 36853224, PMID 37068952, PMID 37947276, PMID 38334499, PMID 39331470, PMID 39455063, PMID 39673415, PMID 40444214, PMID 40482854, PMID 41092316, PMID 41442197, PMID 42133432, PMID 42175562, PMID 42275148, PMID 42384439, PMID 10676716, PMID 10737279, PMID 11328918, PMID 11511139
2023 (13), 2025 (8), 2018 (7), 2019 (7), 2016 (5), 2017 (5), 2014 (4), 2015 (4), 2009 (2), R01DK131091 (2), R01DK141114 (2), U54DK083912 (2), 2005 (1), 2008 (1), 5RC2DK122397 (1)